Arcus Biosciences
biopharmaceutical company
RCUS NYSE
SEC CIK 1724521
Follow Arcus Biosciences
Weekly email: filings, results
Revenue, last quarter
$3M
−50% vs same quarter last year
Net income
−$128M
+5.2% vs same quarter last year
EPS, diluted
−$1.00
+21.3% vs same quarter last year
Operating cash flow
−$88M
+9.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $33M | −$353M |
| FY24 | $51M | −$283M |
| FY23 | $37M | −$307M |
| FY22 | $38M | −$267M |
| FY21 | $383M | $53M |
| FY20 | $78M | −$123M |
| FY19 | $15M | −$84.7M |
| FY18 | $8.4M | −$49.6M |
| FY17 | $1.4M | −$53.1M |
| FY16 | - | −$18M |
| FY15 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1169.7% | −1069.7% |
| FY24 | −647.1% | −554.9% |
| FY23 | −918.9% | −829.7% |
| FY22 | −736.8% | −702.6% |
| FY21 | 14.1% | 13.8% |
| FY20 | −159% | −157.7% |
| FY19 | −591.4% | −564.7% |
| FY18 | −656.8% | −593.7% |
| FY17 | −3782.1% | −3756.7% |
| FY16 | - | - |
| FY15 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$484M |
| FY24 | −$176M |
| FY23 | −$330M |
| FY22 | $432M |
| FY21 | −$282M |
| FY20 | $108M |
| FY19 | −$75.4M |
| FY18 | −$46.7M |
| FY17 | −$30.6M |
| FY16 | −$17M |
| FY15 | - |
- Arcus Biosciences
- Healthcare median
Show the numbers
| Year | Arcus Biosciences | Healthcare median |
|---|---|---|
| FY25 | −1069.7% | −30.6% |
| FY24 | −554.9% | −47% |
| FY23 | −829.7% | −58% |
| FY22 | −702.6% | −80.4% |
| FY21 | 13.8% | −71.8% |
| FY20 | −157.7% | −62.2% |
| FY19 | −564.7% | −46.2% |
| FY18 | −593.7% | −49.6% |
| FY17 | −3756.7% | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |